ストックスクリーナーアプリを入手
4.57
57.04%
1.66
アフターアワーズ：
4.73
0.16
+3.50%
前日終値:
$2.91
開ける：
$5.75
24時間の取引高:
22.97M
Relative Volume:
55.51
時価総額：
$39.95M
収益：
-
当期純損益:
-
株価収益率:
-6.4439
EPS:
-0.7092
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+36.83%
1か月 パフォーマンス:
+30.57%
6か月 パフォーマンス:
+178.66%
1年 パフォーマンス:
+101.32%
1日の値動き範囲:
$4.07
$5.87
1週間の範囲:
$2.76
$5.87
52週間の値動き範囲:
$1.001
$5.87
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
ATHE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.57 | 39.95M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr (ATHE) 最新ニュース
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa
Alterity Therapeutics reports annual general meeting results - Investing.com India
Alterity Therapeutics announces change in company secretary - Investing.com
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Alterity Therapeutics Ltd Adr (ATHE) 財務データ
Alterity Therapeutics Ltd Adr (ATHE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):